Compositions and methods for the analysis of loop-mediated amplification of cell-free DNA
The 2-step PCR-LAMP method addresses the limitations of conventional LAMP assays by generating concatemers to improve DNA sequencing accuracy and detect low-abundance cell-free DNA fragments, reducing sequencing errors and enabling timely clinical diagnosis.
Patent Information
- Application Number
- PCT/US2024/029247
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-15
- Filing Date
- 2024-05-14
- Publication Date
- 2024-11-21
AI Technical Summary
Conventional loop-mediated isothermal amplification (LAMP) assays face challenges in analyzing cell-free DNA due to its short fragment length and low abundance, leading to poor performance in capturing small DNA fragments and high error rates in sequencing, especially in multiplex formats and platforms.
A 2-step amplification method combining polymerase chain reaction (PCR) with LAMP, using forward internal and backward internal LAMP primers to generate concatemers, which reduces sequencing errors and improves the detection of short DNA fragments in samples like plasma and cerebrospinal fluid.
This approach enhances the accuracy and reliability of DNA sequencing by correcting random and systematic errors, enabling the detection of low-abundance cell-free tumor DNA fragments and reducing false positive error rates, facilitating same-day molecular diagnosis in clinical settings.
Smart Images

Figure IMGF000034_0001 
Figure IMGF000034_0002 
Figure IMGF000015_0001
Abstract
Description
[0001] COMPOSITIONS AND METHODS FOR THE ANALYSIS OF LOOP-MEDIATED AMPLIFICATION OF CELL-FREE DNA
[0002] SEQUENCE LISTING
[0003] The text of the computer readable sequence listing filed herewith, titled “41911- 601 SEQUENCE LISTING”, created May 13, 2024, having a file size of 36,784 bytes, is hereby incorporated by reference in its entirety.
[0004] FIELD
[0005] Provided herein are compositions, systems, kits, and methods for the analysis of nucleic acids. In particular, provided herein are reagents and methodologies for the analysis of nucleic acids for research, disease screening, diagnostic, and therapeutic purposes comprising 2-step amplification.
[0006] BACKGROUND
[0007] Loop-mediated isothermal amplification (LAMP) provides concatemeric amplification of DNA targets. (Notomi T et al. Loop-mediated isothermal amplification of DNA. Nucleic Acids Res. 2000 Jun 15,28(I2):E63. doi: 10.1093 / nar / 28. I2,e63. PMID: 10871386; PMCID: PMCI02748. Nagamine K et al. Accelerated reaction by loop-mediated isothermal amplification using loop primers. Mol Cell Probes. 2002 Jun, 16(3):223-9. doi: 10.1006 / mcpr.2002.0415. PMID: 12144774.) LAMP amplifies a nucleic acid thereby increasing its mass, and self-extends copies of the amplified target nucleic acid with additional copies to generate a concatemer. LAMP concatemers serve to resolve sequencing errors because each copy of the original target in the concatemer is identical. LAMP concatemers improve the accuracy of sequencing technologies configured to sequence the full length of each concatemer. Error correction is of particular value when the initial amounts of target DNA are low in abundance, for example in sequencing cell-free tumor DNA (cf-tDNA) for mutation detection in a patient’s body fluid with fewer than 100 tumor molecules of interest per milliliter. If the error rate of the sequencing technology is greater than the signal of the tumor DNA, the error rate of the sequencing technology may preclude accurate detection of mutations from single copies of a nucleic acid sequence that lack redundant sequencing information. However, cf-tDNA is often highly fragmented (e.g., <170 DNA base pairs (bps)) whereas LAMP performs with a preferred target length of approximately 200bp or greater. (Ding X et al. Single enzyme-based stem-loop and linear primers co-mediated exponential amplification of short gene sequences. Anal Chim Acta. 2019 Nov 12; 1081 : 193-199. doi: 10.1016 / j .aca.2019.07.055. Epub 2019 Jul 27. PMID: 31446958.) This nucleic acid length constraint impedes use of LAMP for analysis of cell-free DNA. In turn, conventional LAMP assays require templates that are overly long to capture small cf-tDNA fragments in sample body fluids and biopsies and perform poorly in multipletarget multiplex formats and platforms. Accordingly, compositions, systems, kits, and methods are needed for the detection and identification of DNA sequences in samples with short fragments of DNA present in low abundance.
[0008] SUMMARY
[0009] Provided herein are compositions, systems, kits, and methods for the analysis of nucleic acids. In particular, provided herein are reagents and methodologies for the analysis of nucleic acids for research, disease screening, diagnostic, and therapeutic purposes comprising 2-step amplification.
[0010] In some embodiments, the present invention provides a method of detecting a target in a sample from a subject, comprising: amplifying the target to generate an amplification product; amplifying the amplification product with loop mediated amplification (LAMP) wherein the LAMP amplification comprises a forward internal LAMP primer (FIP), a backward internal LAMP primer (BIP), a forward loop primer (FLP) and a backward loop primer (BLP) to generate a LAMP concatemer product; and detecting the target in the sample in the LAMP concatemer product. In some embodiments, the amplifying is polymerase chain reaction (PCR) amplification whereinthe PCR amplification comprises a forward PCR primer and a reverse PCR primer to generate a PCR amplification product. In some embodiments, the FIP overlaps no more than 5bp of nucleic acid sequence of the forward PCR primer, and the BIP overlaps no more than 5bp of nucleic acid sequence of the reverse PCR primer. In some embodiments, the PCR amplification is singleplex PCR or multiplex PCR amplification. In some embodiments, the amplifying is recombinase polymerase amplification (RPA). In some embodiments, the sample is a plasma sample or a cerebrospinal fluid (CSF) sample. In some embodiments, the sample comprises cell-free tumor DNA (cf-tDNA). In some embodiments, the LAMP amplification is isothermal LAMP amplification or temperature-cycled LAMP amplification. In some embodiments, the target is less than 170bp in length. In some embodiments, the sample comprises at least lOng of nucleic acid comprising at least 10 target molecules. In some embodiments, the method comprises correcting for sequencing errors wherein a number of concatemer copies with the target is divided by a number of concatemer copies without the target. In some embodiments, the detecting is sequencing by synthesis sequencing, nanopore sequencing, single molecule real time (SMRT) sequencing, next generation sequencing or third generation long read sequencing. In some embodiments, the method comprises administering an anti-cancer therapy to the subject if the target is detected.
[0011] In some embodiments, the present invention provides a kit comprising one or more amplification primers, a FIP and a BIP wherein the FIP and the BIP overlap no more than 5 bp of nucleic acid sequence the one or more amplification primers, a FLP and a BLP. In some embodiments, the one or more amplification primers comprises a forward PCR primer and a reverse PCR primer. In some embodiments, the one or more amplification primers comprises a forward RPA primer and a reverse RPA primer. In some embodiments, the kit comprises one or more nucleic acid isolation reagents. In some embodiments, the kit comprises one or more PCR amplification reagents. In some embodiments, the kit comprises one or more RPA amplification reagents. In some embodiments, the kit comprises one or more LAMP amplification reagents. In some embodiments, the kit comprises one or more nucleic acid sequencing reagents.
[0012] In some embodiments, the present invention provides a reaction mixture, comprising: an amplification product from cf-tDNA and one or more LAMP reagents configured to detect a target.
[0013] In some embodiments, the present invention provides a method of amplifying a nucleic acid, comprising: amplifying the nucleic acid with PCR amplification to generate a PCR amplification product; and amplifying the PCR amplification product with loop mediated amplification (LAMP) to generate a LAMP concatemer product. In some embodiments, the nucleic acid is cf-tDNA nucleic acid.
[0014] DESCRIPTION OF THE FIGURES
[0015] Fig 1. shows a flowchart of 2-step PCR-LAMP amplification.
[0016] Fig. 2 shows a schematic diagram of capture and PCR amplification of a <170bp fragment of cell-free DNA (cf-DNA), followed by LAMP amplification of the PCR product.
[0017] Fig. 3 shows a panel of 9 LAMP target genes and codon loci.
[0018] Fig. 4 shows a visualization of a polyacrylamide gel electrophoresis (PAGE) of the panel of 9 LAMP target genes and codon loci of Fig. 4. Fig. 5 shows comparative error rate reduction in 2 target genes and codon loci between IGV pileup and methods of the present invention comprising LAMP error correction wherein LAMP concatemers are derived from a single template copy. By comparing forward and reverse complement sections, LAMPrey corrects random sequencing errors in a minority of concatemer copies, and systematic sequencing errors arising from, for example, errors due to variations in chemistry, temperature flux, contaminants, platform errors (e.g. a faulty nanopore), or polymerase error that may be perpetuated along a multiple copy concatemer i.e. a concatemer comprising 2 or more copies of the target. (Wadden J et al. Ultra-rapid somatic variant detection via real-time targeted amplicon sequencing, Commun Biol. 2022 Jul 15;5(l):708. doi: 10.1038 / s42003-022-03657-6. PM ID: 35840782; PMC1D: PMC9284968.)
[0019] Fig. 6 shows reduction in false positive error rate using methods and compositions of the present invention.
[0020] Fig. 7 shows a comparative IGV and LAMPrey limit-of-detection analyses of PDGFRA D842V and BRAF V600E target loci. Cell-free DNA pan-cancer variant reference standards obtained from Twist Bioscience (San Francisco, CA) (SKU 104549; 5%, 2%, 1%, 0.5%, 0.25%, 0.1%) were amplified and sequenced using 2-stage PCR-LAMP amplification of the present invention. In step 1, 30ng of Twist Bioscience pan-cancer reference standard were amplified via PCR (60mins). In step 2, lul of the step 1 PCR product was added to parallel LAMP reactor vessels for 30-90 minutes. In sequencing library preparation, LAMP products were combined with the Nanopore Rapid Barcoding kit (RBK004) (30mins), and the libraries were sequenced by a MinlON R9.4.1 flow-cell (l-4hrs). Nucleic acid bases were identified using the Guppy 6.4.2 super accuracy model, and lamplicons were aligned using minimap2 under standard Oxford Nanopore (Oxford Science Park, UK) options (-x map-ont). Sequencing data with 3 or more concatemers were analyzed for error correction using the methods of Wadden et al., 2022 (ibid.)
[0021] Fig. 8 shows an example schematic diagram of the relationship between LAMP F2 / B2 regions in FIP / BIP primers for a H3FA L27M assay.
[0022] Fig. 9 shows the false positive error rates of nanopore sequencing of the H3.3 K27M locus. Error bars indicate S.D.s
[0023] Fig. 10 shows comparative false positive error rate of nanopore sequencing of the H3.3 K27M locus. Error bars indicate S.D.s.
[0024] Fig. 11 shows patient plasma samples from a first patient measured using the LAMP assay and the droplet digital PCR (ddPCR) technique. Fig. 12 shows patient plasma samples from a second patient measured using the LAMP assay and the droplet digital PCR (ddPCR) technique.
[0025] Fig. 13 shows patient plasma samples from a third patient measured using the LAMP assay and the droplet digital PCR (ddPCR) technique.
[0026] Fig. 14 shows patient plasma samples from a fourth patient measured using the LAMP assay and the droplet digital PCR (ddPCR) technique.
[0027] DEFINITIONS
[0028] Throughout the specification and claims, the following terms take the meanings explicitly associated herein, unless the context clearly dictates otherwise. The phrase “in some embodiments” as used herein does not necessarily refer to the same embodiment, though it may. Thus, as described below, various embodiments of the invention may be readily combined, without departing from the scope or spirit of the invention.
[0029] In addition, as used herein, the term “or” is an inclusive “or” operator and is equivalent to the term “and / or” unless the context clearly dictates otherwise. The term “based on” is not exclusive and allows for being based on additional factors not described, unless the context clearly dictates otherwise. In addition, throughout the specification, the meaning of “a,” “an,” and “the” include plural references. The meaning of “in” includes “in” and “on.”
[0030] The term “one or more,” as used herein, refers to a number higher than one. For example, the term “one or more” encompasses any of the following: two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, ten or more, eleven or more, twelve or more, thirteen or more, fourteen or more, fifteen or more, twenty or more, fifty or more, 100 or more, or an even greater number.
[0031] The term “one or more but less than a higher number,” “two or more but less than a higher number,” “three or more but less than a higher number,” “four or more but less than a higher number,” “five or more but less than a higher number,” “six or more but less than a higher number,” “seven or more but less than a higher number,” “eight or more but less than a higher number,” “nine or more but less than a higher number,” “ten or more but less than a higher number,” “eleven or more but less than a higher number,” “twelve or more but less than a higher number,” “thirteen or more but less than a higher number,” “fourteen or more but less than a higher number,” or “fifteen or more but less than a higher number” is not limited to a higher number. For example, the higher number can be 10,000, 1,000, 100, 50, etc. For example, the higher number can be approximately 50 (e.g., 50, 49, 48, 47, 46, 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 32, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3 or 2).
[0032] As used herein, “error correction” refers to correction of errors that arise in sequencing a nucleic acid template. In some embodiments, error correction is supported because each sub-section of a concatemer that is accurately sequenced contains the identical sequence derived from the original template strand. Because of concatemer redundancy, concatemeric error correction succeeds at correcting random sequencing errors with multiple concatemer copies sequenced. For example, if 2 concatemer subsections are discordant (z.e., dual modular redundancy) an error is identified. Similarly, if % of concatemer subsections agree, these are assumed accurate and that the third subsection is in error. Thus, three or more concatemer subsections serve to correct random sequencing errors (e.g., triple modular redundancy).
[0033] As used herein, “multiplex” refers to the simultaneous amplification of different nucleic acid templates with different template-specific primer pairs in a shared vessel with shared amplification reagents (e.g., shared choice and concentrations of pH, buffers, ions, etc.) and shared amplification conditions (e.g., thermocycling conditions).
[0034] The term “next generation sequencing” refers to highly parallelized methods of performing nucleic acid sequencing and comprises the sequencing-by-synthesis or sequencing-by-ligation platforms (e.g., employed by Illumina, Life Technologies, Pacific Biosciences and Roche etc.). Next generation sequencing methods may also include, but not be limited to, nanopore sequencing methods such as offered by Oxford Nanopore or electronic detection-based methods such as the Ion Torrent technology commercialized by Life Technologies.
[0035] As used herein, the term “circulating tumor DNA” (or “ctDNA”) is tumor-derived DNA that is circulating in the peripheral blood of a patient. ctDNA is of tumor origin and originates directly from the tumor or from circulating tumor cells (CTCs), which are viable, intact tumor cells that shed from primary tumors and enter the bloodstream or lymphatic system. The term “cf-tDNA” refers to cell free tumor DNA in a circulating or noncirculating body fluid.
[0036] As used herein, a “nucleic acid” or “nucleic acid molecule” generally refers to any ribonucleic acid or deoxyribonucleic acid, which may be unmodified or modified DNA or RNA. “Nucleic acids” include, without limitation, single- and double-stranded nucleic acids. As used herein, the term “nucleic acid” also includes DNA as described above that contains one or more modified bases. Thus, DNA with a backbone modified for stability or for other reasons is a “nucleic acid.” The term “nucleic acid” as it is used herein embraces such chemically, enzymatically, or metabolically modified forms of nucleic acids, as well as the chemical forms of DNA characteristic of viruses and cells, including for example, simple and complex cells.
[0037] The terms “oligonucleotide” or “polynucleotide” or “nucleotide” or “nucleic acid” refer to a molecule having two or more deoxyribonucleotides or ribonucleotides, preferably more than three, and usually more than ten. The exact size will depend on many factors, which in turn depends on the ultimate function or use of the oligonucleotide. The oligonucleotide may be generated in any manner, including chemical synthesis, DNA replication, reverse transcription, or a combination thereof. Typical deoxyribonucleotides for DNA are thymine, adenine, cytosine, and guanine. Typical ribonucleotides for RNA are uracil, adenine, cytosine, and guanine.
[0038] As used herein, the terms “locus” or “region” of a nucleic acid refer to a subregion of a nucleic acid, e.g., a gene on a chromosome, a single nucleotide, etc.
[0039] The terms “complementary” and “complementarity” refer to nucleotides (e.g., 1 nucleotide) or polynucleotides (e.g., a sequence of nucleotides) related by the base-pairing rules. For example, the sequence 5’-A-G-T-3’ is complementary to the sequence 3'-T-C-A-5'. Complementarity may be “partial,” in which only some of the nucleic acids’ bases are matched according to the base pairing rules. Or, there may be “complete” or “total” complementarity between the nucleic acids. The degree of complementarity between nucleic acid strands effects the efficiency and strength of hybridization between nucleic acid strands. This is of particular importance in amplification reactions and in detection methods that depend upon binding between nucleic acids.
[0040] The term “gene” refers to a nucleic acid (e.g., DNA or RNA) sequence that comprises coding sequences necessary for the production of an RNA, or of a polypeptide or its precursor. A functional polypeptide can be encoded by a full-length coding sequence or by any portion of the coding sequence as long as the desired activity or functional properties (e.g., enzymatic activity, ligand binding, signal transduction, etc.) of the polypeptide are retained. The term “portion” when used in reference to a gene refers to fragments of that gene. The fragments may range in size from a few nucleotides to the entire gene sequence minus one nucleotide. Thus, “a nucleotide comprising at least a portion of a “gene” may comprise fragments of the gene or the entire gene.
[0041] The term “gene” also encompasses the coding regions of a structural gene and includes sequences located adjacent to the coding region on both the 5' and 3' ends, e.g., for a distance of about 1 kb on either end, such that the gene corresponds to the length of the full- length mRNA (e.g., comprising coding, regulatory, structural and other sequences). The sequences that are located 5' of the coding region and that are present on the mRNA are referred to as 5' non-translated or untranslated sequences. The sequences that are located 3' or downstream of the coding region and that are present on the mRNA are referred to as 3' nontranslated or 3' untranslated sequences. The term “gene” encompasses both cDNA and genomic forms of a gene. In some organisms (e.g., eukaryotes), a genomic form or clone of a gene contains the coding region interrupted with non-coding sequences termed “introns” or “intervening regions” or “intervening sequences.” Introns are segments of a gene that are transcribed into nuclear RNA (hnRNA); introns may contain regulatory elements such as enhancers. Introns are removed or “spliced out” from the nuclear or primary transcript; introns therefore are absent in the messenger RNA (mRNA) transcript. The mRNA functions during translation to specify the sequence or order of amino acids in a nascent polypeptide.
[0042] In addition to containing introns, genomic forms of a gene may also include sequences located on both the 5' and 3' ends of the sequences that are present on the RNA transcript. These sequences are referred to as “flanking” sequences or regions (these flanking sequences are located 5' or 3' to the non-translated sequences present on the mRNA transcript). The 5' flanking region may contain regulatory sequences such as promoters and enhancers that control or influence the transcription of the gene. The 3' flanking region may contain sequences that direct the termination of transcription, posttranscriptional cleavage, and polyadenylation.
[0043] The term “wild-type” when made in reference to a gene refers to a gene that has the characteristics of a gene isolated from a naturally occurring source. The term “wild-type” when made in reference to a gene product refers to a gene product that has the characteristics of a gene product isolated from a naturally occurring source. The term “wild-type” when made in reference to a protein refers to a protein that has the characteristics of a naturally occurring protein. The term “naturally-occurring” as applied to an object refers to the fact that an object can be found in nature. For example, a polypeptide or polynucleotide sequence that is present in an organism (including viruses) that can be isolated from a source in nature, and which has not been intentionally modified by the hand of a person in the laboratory is naturally-occurring. A wild-type gene is often that gene or allele that is most frequently observed in a population and is thus arbitrarily designated the “normal” or “wild-type” form of the gene. In contrast, the term “modified” or “mutant” when made in reference to a gene or to a gene product refers, respectively, to a gene or to a gene product that displays modifications in sequence and / or functional properties (e.g., altered characteristics) when compared to the wild-type gene or gene product. It is noted that naturally-occurring mutants can be isolated; these are identified by the fact that they have altered characteristics when compared to the wild-type gene or gene product.
[0044] The term “allele” refers to a variation of a gene; the variations include but are not limited to variants and mutants, polymorphic loci, and single nucleotide polymorphic loci, frameshift, and splice mutations. An allele may occur naturally in a population, or it might arise during the lifetime of any particular individual of the population.
[0045] Thus, the terms “variant” and “mutant” when used in reference to a nucleotide sequence refer to a nucleic acid sequence that differs by one or more nucleotides from another, usually related, nucleotide acid sequence. A “variation” is a difference between two different nucleotide sequences; typically, one sequence is a reference sequence.
[0046] As used herein, “integrated genome viewer (IGV)” is a computer program used to visualize sequence reads aligned to a reference genome. “IGV pileup” describes all sequence reads aligned to a specific location that create a stack. Allele fractions can be computed by examination at a specific genomic coordinate on the pileup, and reporting mutant alleles versus wild-type alleles (e.g., VAF = mut / (mut+wt) * 100). The precise allele fraction is a consequence of all wet lab and bio-informatic analysis. IGV pileup is an efficient method of visualizing and computing VAFs. A “false discovery rate” is computed as the VAF of mutant alleles when sequencing a known wild-type target.
[0047] The term “primer” refers to an oligonucleotide, whether occurring naturally as, e.g., a nucleic acid fragment from a restriction digest, or produced synthetically, that is capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product that is complementary to a nucleic acid template strand is induced, (e.g., in the presence of nucleotides and an inducing agent such as a DNA polymerase, and at a suitable temperature and pH). The primer is preferably single stranded for maximum efficiency in amplification but may alternatively be double stranded. If double stranded, the primer is first treated to separate its strands before being used to prepare extension products. Preferably, the primer is an oligodeoxyribonucleotide. The primer must be sufficiently long to prime the synthesis of extension products in the presence of the inducing agent. The exact lengths of the primers will depend on many factors, including temperature, source of primer, and the use of the method.
[0048] The term “probe” refers to an oligonucleotide (e.g., a sequence of nucleotides), whether occurring naturally as in a purified restriction digest or produced synthetically, recombinantly, or by PCR amplification, which is capable of hybridizing to another oligonucleotide of interest. A probe may be single-stranded or double-stranded. Probes are useful in the detection, identification, and isolation of particular nucleic acid sequences (e.g., a “capture probe”). It is contemplated that any probe used in the embodiments of the present disclosure may, in some embodiments, be labeled with any “reporter molecule,” so that is detectable in any detection system, including, but not limited to enzyme (e.g., ELISA, as well as enzyme-based histochemical assays), fluorescent, radioactive, and luminescent systems. It is not intended that the various embodiments of the present disclosure be limited to any particular detection system or label.
[0049] The term “target,” as used herein refers to a nucleic acid sought to be sorted out from other nucleic acids, e.g., by probe binding, amplification, isolation, capture, etc. For example, when used in reference to the polymerase chain reaction, “target” refers to the region of nucleic acid bounded by the primers used for polymerase chain reaction, while when used in an assay in which target DNA is not amplified.
[0050] Accordingly, as used herein, “non-targef ’, e.g., as it is used to describe a nucleic acid such as a DNA, refers to nucleic acid that may be present in a reaction, but that is not the subject of detection or characterization by the reaction. In some embodiments, non-target nucleic acid may refer to nucleic acid present in a sample that does not, e.g., contain a target sequence, while in some embodiments, non-target may refer to exogenous nucleic acid, i.e., nucleic acid that does not originate from a sample containing or suspected of containing a target nucleic acid, and that is added to a reaction, e.g., to normalize the activity of an enzyme (e.g., polymerase) to reduce variability in the performance of the enzyme in the reaction.
[0051] As used herein, a “diagnostic” test application includes the detection or identification of a disease state or condition of a subject, determining the likelihood that a subject will contract a given disease or condition, determining the likelihood that a subject with a disease or condition will respond to therapy, determining the prognosis of a subject with a disease or condition (or its likely progression or regression), and / or determining the effect of a treatment on a subject with a disease or condition. For example, a diagnostic test can be used for detecting the presence or likelihood of a subject contracting a neoplasm or the likelihood that such a subject will respond favorably to a compound (e.g., a pharmaceutical, e.g., a drug) or other treatment.
[0052] The term “isolated” when used in relation to a nucleic acid, as in “an isolated oligonucleotide” refers to a nucleic acid sequence that is identified and separated from at least one contaminant nucleic acid with which it is ordinarily associated in its natural source. Isolated nucleic acid is present in a form or setting that is different from that in which it is found in nature. In contrast, non-isolated nucleic acids, such as DNA and RNA, are found in the state they exist in nature. Examples of non-isolated nucleic acids include a given DNA sequence (e.g., a gene) found on the host cell chromosome in proximity to neighboring genes; RNA sequences, such as a specific mRNA sequence encoding a specific protein, found in the cell as a mixture with numerous other mRNAs which encode a multitude of proteins. However, isolated nucleic acid encoding a particular protein includes, by way of example, such nucleic acid in cells ordinarily expressing the protein, where the nucleic acid is in a chromosomal location different from that of natural cells, or is otherwise flanked by a different nucleic acid sequence than that found in nature. The isolated nucleic acid or oligonucleotide may be present in single-stranded or double-stranded form. When an isolated nucleic acid or oligonucleotide is to be utilized to express a protein, the oligonucleotide will contain at a minimum the sense or coding strand (i.e., the oligonucleotide may be singlestranded), but may contain both the sense and anti-sense strands (i.e., the oligonucleotide may be double-stranded). An isolated nucleic acid may, after isolation from its natural or typical environment, be combined with other nucleic acids or molecules. For example, an isolated nucleic acid may be present in a host cell into which it has been placed, e.g., for heterologous expression.
[0053] The term “purified” refers to molecules, either nucleic acid or amino acid sequences that are removed from their natural environment, isolated, or separated. An “isolated nucleic acid sequence” may therefore be a purified nucleic acid sequence. “Substantially purified” molecules are at least 60% free, preferably at least 75% free, and more preferably at least 90% free from other components with which they are naturally associated. As used herein, the terms “purified” or “to purify” also refer to the removal of contaminants from a sample. The removal of contaminating proteins results in an increase in the percent of polypeptide or nucleic acid of interest in the sample. In another example, recombinant polypeptides are expressed in plant, bacterial, yeast, or mammalian host cells and the polypeptides are purified by the removal of host cell proteins; the percent of recombinant polypeptides is thereby increased in the sample.
[0054] As used herein, the terms “patient” or “subject” refer to organisms to be subject to various tests described herein. The term “subject” includes animals, preferably mammals, including humans. In a preferred embodiment, the subject is a primate. In an even more preferred embodiment, the subject is a human. Further with respect to diagnostic methods, a preferred subject is a vertebrate subject. A preferred vertebrate is warm-blooded; a preferred warm-blooded vertebrate is a mammal. A preferred mammal is most preferably a human. As used herein, the term “subject” includes both human and animal subjects. Thus, veterinary therapeutic uses are provided herein. As such, the present disclosure provides for the diagnosis of mammals such as humans, as well as those mammals of importance due to being endangered, such as Siberian tigers; of economic importance, such as animals raised on farms for consumption by humans; and / or animals of social importance to humans, such as animals kept as pets or in zoos. Examples of such animals include but are not limited to carnivores such as cats and dogs; swine, including pigs, hogs, and wild boars; ruminants and / or ungulates such as cattle, oxen, sheep, giraffes, deer, goats, bison, and camels; pinnipeds; and horses. Thus, also provided is the diagnosis and treatment of livestock, including, but not limited to, domesticated swine, ruminants, ungulates, horses (including racehorses), and the like.
[0055] As used herein, the term “kit” refers to any delivery system for delivering materials. In the context of reaction assays, such delivery systems include systems that allow for the storage, transport, or delivery of reaction reagents (e.g., oligonucleotides, enzymes, etc. in the appropriate containers) and / or supporting materials (e.g., buffers, written instructions for performing the assay etc.) from one location to another. For example, kits include one or more enclosures (e.g., boxes) containing the relevant reaction reagents and / or supporting materials. As used herein, the term “fragmented kit” refers to delivery systems comprising two or more separate containers that each contain a sub-portion of the total kit components. The containers may be delivered to the intended recipient together or separately. For example, a first container may contain an enzyme for use in an assay, while a second container contains oligonucleotides. The term “fragmented kit” is intended to encompass kits containing Analyte specific reagents (ASR’s) regulated under the Federal Food, Drug, and Cosmetic Act, but are not limited thereto. Indeed, any delivery system comprising two or more separate containers that each contains a sub-portion of the total kit components are included in the term “fragmented kit.” In contrast, a “combined kit” refers to a delivery system containing all of the components of a reaction assay in a single container (e.g., in a single box housing each of the desired components). The term “kit” includes both fragmented and combined kits.
[0056] As used herein, the term “information” refers to any collection of facts or data. In reference to information stored or processed using a computer system(s), including but not limited to internets, the term refers to any data stored in any format (e.g., analog, digital, optical, etc.). As used herein, the term “information related to a subject” refers to facts or data pertaining to a subject (e.g., a human, plant, or animal). The term “genomic information” refers to information pertaining to a genome including, but not limited to, nucleic acid sequences, genes, percentage methylation, allele frequencies, RNA expression levels, protein expression, phenotypes correlating to genotypes, etc.
[0057] As used herein, the terms “sample,” “test sample,” and “biological sample” refer to a sample containing or suspected of containing a biomarker of the present disclosure. The sample may be derived from any suitable source. In some cases, the sample may comprise a liquid, fluent particulate solid, or fluid suspension of solid particles. In some cases, the sample may be processed prior to the analysis described herein. For example, the sample may be separated or purified from its source prior to analysis. In a particular example, the source is a mammalian (e.g., human) bodily substance (e.g., bodily fluid, blood such as whole blood, buffy coat, serum, plasma, urine, saliva, sweat, sputum, semen, mucus, lacrimal fluid, lymph fluid, amniotic fluid, interstitial fluid, cerebrospinal fluid, feces, tissue, organ, one or more dried blood spots, or the like). The sample may be a liquid sample or a liquid extract of a solid sample. In some embodiments, the source of the sample may be an organ or tissue, such as a biopsy sample and / or an endoscopic brushing sample (e.g., endoscopic esophageal brushing sample), which may be solubilized by tissue disintegration / cell lysis. Samples can be obtained by any number of methodologies. Cell free or substantially cell free samples can be obtained by subjecting the sample to various techniques including but are not limited to, centrifugation and filtration. In some embodiments, nucleic acid is isolated from a sample (e.g., a tissue sample, a blood sample, a plasma sample, a serum sample, a whole blood sample, a buffy coat sample, a secretion sample, an organ secretion sample, a cerebrospinal fluid (CSF) sample, a saliva sample, a urine sample, and / or a stool sample) using direct gene capture, e.g., as detailed in U.S. Pat. Nos. 8,808,990 and 9,169,511, and in WO 2012 / 155072, or by a related method.
[0058] DETAILED DESCRIPTION
[0059] Provided herein are compositions, systems, kits, and methods for the analysis of nucleic acids. In particular, provided herein are reagents and methodologies for the analysis of nucleic acids for research, disease screening, diagnostic, and therapeutic purposes comprising 2-step amplification. Exemplary, non-limiting compositions, systems, kits and methods are described below.
[0060] In some embodiments, the present invention provides compositions, systems, kits and methods for first-step singleplex or multiplex polymerase chain reaction (PCR) amplification of a target DNA template, followed by second-step LAMP amplification of the PCR amplification product with a LAMP forward internal primer (FIP) and a LAMP backward internal primer (BIP). (Figure 1, Figure 2) In some embodiments, the compositions, systems, kits and methods further comprise a forward LAMP loop primer (FLP) and a backward LAMP loop primer (FLP). In some embodiments, the compositions, systems, kits and methods of the present invention do not employ a LAMP forward external primer (F3) or a LAMP backward external primer (B3). In some embodiments, the first-step PCR amplification is a multiplex PCR amplification to simultaneously capture and amplify two or more DNA fragments, and the second-step comprises parallel singleplex parallel LAMP reactors to simultaneously or sequentially contcatemerize one or more PCR products. In some embodiments, antecedent singleplex or multiplex polymerase PCR amplification captures and amplifies low abundance, small cf-tDNA fragments (e.g., < 170bp) to generate an amount of PCR amplification product sufficient for use as a template for FIP / BIP LAMP amplification without F3 and B3 primers. In some embodiments, the antecedent cf-tDNA fragments are greater than 170bp to generate an amount of PCR amplification product sufficient for use as a template for FIP / BIP LAMP amplification without F3 and B3 primers. First-step PCR primers are designed to generate amplicons that comprise a complementary portion of the F2 region of the FIP primer and the B2 region of the BIP primer such that the F2-B2 region of the PCR amplification product comprises <170bp. (Table 1)
[0061] TABLE 1.
[0062] Multiplex PCR Primer Panel
[0063] In some embodiments, the present invention provides compositions, systems, kits and methods for error correction in concatemers generated from samples comprising less than 1% variant allele frequency (e.g., less than 0.5%, less than 0.1%, etc.) in a fluid sample (e.g., a blood sample or cerebrospinal fluid sample) comprising at least lOng (e.g., at least 20ng, at least 50ng, etc.) of target nucleic acid template comprising at least 10 target molecules (e.g, at least 20 target molecules, at least 50 target molecules, at least 100 target molecules) for detection. In some embodiments, the present invention provides compositions, systems, kits and methods for error correction in concatemers generated from samples comprising greater than 1% variant allele frequency (e.g., greater than 2%, greater than 5%, etc.) in a fluid sample (e.g., a blood sample or cerebrospinal fluid sample) comprising at least lOng (e.g., at least 20ng, at least 50ng, etc.) of target nucleic acid template comprising at least 10 target molecules (e.g., at least 20 target molecules, at least 50 target molecules, at least 100 target molecules) for detection. In some embodiments, the compositions, systems, kits and methods comprising 2-step amplification reduce bias arising from differential (i.e., uneven) rates of amplification from initial template molecules compared to single step LAMP -based technologies used alone, and provide an accurate assessment of a sample’s starting ratio of small DNA tumor fragments to healthy DNA fragments of use in disease diagnosis and therapy monitoring. (Cantor E et al. Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma. Neuro Oncol. 2022 Aug 1 ;24(8): 1366- 1374. doi: 10.1093 / neuonc / noac030. PMID: 35137228; PMCID: PMC9340643.)
[0064] In some embodiments, the compositions, systems, kits and methods of the present invention find use in the diagnosis and management of cancer. For example, brain tumors may be difficult to diagnose and to monitor using conventional neuro-imaging. Quantitative liquid (e.g., cerebrospinal fluid (CSF) and blood) biopsy provide an alternative. However, CSF samples may be difficult to collect in children and many adults, and the amounts of cf- tDNA may be insufficient in plasma after filtration by the blood brain barrier with allele fractions ranging between 0.01% and 0.5%. In turn, error rates of conventional sequencing platforms (e.g., Oxford Nanopore sequencing) may be greater than signals from targeted cf- tDNA DNA templates. Droplet-digital PCR (ddPCR) is a sensitive and accurate method to quantify rare mutations in patient samples for treatment monitoring, but assay design and validation is expensive and time consuming. In turn, each ddPCR assay is allele-specific thereby limiting its ability to track multiple patient-specific mutations. This further constrains the applicability of assays across cancer patients given that patients might not have overlapping mutations, thereby increasing assay design and validation burdens in cases when patients have mutations that are rare. A further drawback of ddPCR is high capital expenditures required to acquire and maintain ddPCR machinery versus handheld sequencers. Circular concatemerization and consensus sequencing approaches require up to 3 days to complete protocols and are incompatible with same-day clinic visits and timely amendments to patient care. Conventional 4-6 primer isothermal LAMP amplification is ill-suited to capturing low abundance, highly fragmented cf-tDNA fragments.
[0065] To surmount these limitations, experiments conducted in the development of the present invention achieved multiplexed concatemerization of short (for example <200bp, or < 170bp), low abundance DNA targets using a 2-step amplification approach with coordinated and co-designed multiplex PCR primers and 2-primer BIP / FIP LAMP primers. To accurately detect and identify low abundance cf-tDNA in plasma and in CSF from, for example, brain tumors, a first amplification step comprised multiplex PCR to capture and amplify small cf- tDNA fragments, and a second parallel singleplex LAMP vessels to concatemerize PCR product. The products of the second step LAMP amplification may then be characterized by any suitable nucleic acid sequencing method including, for example, Oxford Nanopore sequencing for same day molecular diagnosis, (see e.g., Experimental Example 1) In some embodiments, the compositions, systems, kits and methods of the present invention comprise a multiplex PCR panel comprising, for example, PCR primers (e.g., at 0.16uM final concentration), PCR amplification reagents (e.g., New England Biolabs Q5 2x Hot Start Master Mix (#M0494) following manufacturer guidelines with, for example 25ul Q5 master mix, 20ul nuclease free water), input cell free DNA, and a PCR amplification protocol (e.g., comprising 30s @ 98C, 35 cycles of 10s @ 98C, 45s @ 63C, 10s @ 72C, and 2min @ 72C).
[0066] In some embodiments, LAMP amplification is isothermal amplification. In embodiments, LAMP amplification is thermal / temperature cycling LAMP amplification. In some embodiments, a plurality of singleplex reactions in singleplex reaction vessels are performed simultaneously or sequentially in a shared thermocycler with shared thermocycling program conditions.
[0067] In some embodiments of the present invention, LAMP primers are designed using
[0068] Eiken Primer Explorer v5 or the NEB (Ipswich, MA) LAMP design tool. (Table 2). TABLE 2.
[0069] LAMP Primer Sequences
[0070] Outer bump primers criteria (for example, the distance in bp between F3 / B3 primers, primer length size, GC content and melting temperature) are adjusted to provide primer design algorithms with the ability to identify optimal FIP / BIP pairs without restriction and without the need for F3 / B3 primers to perform LAMP. LAMP assay designs with: 1) an F2 / B2 span less than 170bp, and 2) optimal thermodynamics in keeping with conventional LAMP primer design protocols comprising design regions (F1 / F2 / B1 / B2) but 3) not covering the mutation of interest are selected. Candidate LAMP assays are tested for amplification rates and ability to generate concatemeric products on human genomic DNA templates with temperature cycling (64°C< - >68°C) without inclusion of F3 / B3 bump primers. LAMP assays that pass validation are identified as substrates for multiplex PCR target capture panel design.
[0071] In some embodiments, after the design of validated LAMP assays for a target template of interest, a panel of PCR primers are designed to amplify specific regions for subsequent LAMP amplification using, for example, the following criteria: 1) The amplicon produced by each forward / reverse primer pair is not larger than a designated short length (e.g., 170bp) to promote capture of small cf-tDNA fragments.
[0072] 2) In some embodiments the forward primer resides outside of the F2 region. In some embodiments the forward primer is partially within the F2 region. In some embodiments, primer design software is restricted to search for FIP candidates starting up to 5bp within the 5’ end of the F2 region for a specific LAMP assay.
[0073] 3) The reverse primer is co-designed in a parallel fashion. In some embodiments, the reverse primer resides outside of the B2 region. In some embodiments the reverse primer is partially within the B2 region. In some embodiments, primer design software is restricted to search for BIP candidates starting up to 5bp within the 3’ end of the B2 region for a specific LAMP assay, with a distance between forward and reverse PCR primers less than the designated short length (e.g., 170bp), and as short in length as compatible to amplify a target template flanking a nucleic acid locus of interest.
[0074] In some embodiments the compositions, systems, kits and methods of the present invention comprise a parallel singleplex LAMP amplification comprising, for example, primers mixed according to LAMP master mix manufacturer specifications into lOx master mixes with FIP: 16uM, BIP: 16uM BLP: 4uM, FLP: 4uM, and reactions performed with NEB WarmStart LAMP 2x Master Mix (#M1700) following manufacturer instructions with a lx reaction mix comprising 12.5ul NEB WarmStart 2x Master Mix, 9ul nuclease free water, 2.5ul lOx primer master mix and lul input template product, with a LAMP protocol comprising cycling between 64C and 68C remaining at each temperature for Is, slowing the ramp rate between temperatures to IC / s, and incubation until the singleplex reactionbecomes visibly cloudy, for example, between 17mins and 80mins.
[0075] Other than the target template region, multiplex PCR primer design is independent of LAMP assay design and may be performed using any desired thermodynamic / reagent / salt criteria for preferred master mix or reaction conditions. In some embodiments high-fidelity polymerases such as NEB’s Q5 hotstart 2x master mix are used to limit PCR error. In some embodiments, multiplex PCR design software (for example, DNASoftware PanelPlex) is used to design candidate panels using the above parameters and an initial target assay melting temperature target of, for example, 63°C.
[0076] In some embodiments, multiplex panels are initially evaluated with each primer pair at a final reaction concentration of, for example, 0.4uM of human genomic DNA. After confirmation of amplification of the multiplex panel (for example, by Qubit fluorometer), amplification of specific templates is confirmed by performing LAMP assays on lul of PCR product as direct input to LAMP amplification. If LAMP amplification occurs and the target product is generated, it is evident that the PCR template was present in sufficient quantity to support LAMP amplification.
[0077] Any sample suspected of containing a nucleic may be tested according to methods of embodiments of the present invention. By way of non-limiting examples, the sample may be tissue (e.g., a biopsy sample), blood, urine, feces, saliva, or a fraction thereof (e.g., plasma, serum, urine supernatant, urine cell pellet, etc.) or environmental samples.
[0078] Any one or more of the DNA targets described herein may be detected along with other markers (e.g., in a multiplex and / or independent format). Other markers include, but are not limited to, nucleic acids (e.g., DNA, RNA, wild-type or mutant, methylated or unmethylated), proteins / peptides (e.g., antibodies), metabolites, infectious disease agents or components thereof, and the like. The markers may provide information about a shared disease or condition (e.g., cancer), a different disease or condition, an infection, a metabolic condition or status, or may be used as a control or normalization marker.
[0079] Nucleic acid may be detected using a variety of techniques including but not limited to: nucleic acid sequencing, nucleic acid hybridization, and nucleic acid amplification.
[0080] Suitable nucleic acid sequencing techniques include, but are not limited to, sequencing by synthesis (see e.g., Meyer and Kircher, "Illumina sequencing library preparation for highly multiplexed target capture and sequencing," Cold Spring Harbor Protocols 2010 (6)); single-molecule real-time sequencing (see e.g., Levene et al., "Zero- Mode Waveguides for Single-Molecule Analysis at High Concentrations," Science. 299(5607): 682-6 (2003)); ion semiconductor sequencing (see e.g., Rusk, “Torrents of sequence,” Nat. Methods 8, 44 (2011)); pyrosequencing (see e.g., Wicker et al., “454 sequencing put to the test using the complex genome of barley,” BMC Genomics, 7:275, 2006); sequencing by ligation (SOLiD sequencing) (see e.g., Margulies et al., “Genome sequencing in microfabricated high-density picolitre reactors,” Nature, 437:376-80 (2005)); nanopore sequencing (see e.g., Goodwin et al., “Oxford Nanopore sequencing, hybrid error correction, and de novo assembly of a eukaryotic genome,” Genome Res., 25(11): 1750-6 (2015)); chain termination sequencing (Sanger sequencing) (see e.g., Sanger et al., "DNA sequencing with chain-terminating inhibitors, "Proceedings of the National Academy of Sciences of the United States of America, 74 (12): 5463-5467 (1977)); and sequencing with mass spectrometry (see e.g., Edwards et al., "Mass-spectrometry DNA sequencing," Mutation Research, 573(1-2): 3-12 (2005)).
[0081] Suitable hybridization techniques include, but are not limited to, in situ hybridization (ISH), microarray, Southern or Northern blot, hybrid capture, and direct or indirect detection of enzymatically modified hybridization complexes.
[0082] Nucleic acid variations may be detected by amplification reactions coupled with probe-based detection or sequencing. Nucleic acids may be amplified prior to or simultaneous with detection. Illustrative non-limiting examples of nucleic acid amplification techniques include, but are not limited to, polymerase chain reaction (PCR), TAQMAN amplification, reverse transcription polymerase chain reaction (RT-PCR), quantitative allelespecific real-time target and signal amplification (QuARTS), target enrichment long-probe quantitative amplified signal (TELQAS), transcription-mediated amplification (TMA), ligase chain reaction (LCR), strand displacement amplification (SDA), is recombinase polymerase amplification (RPA) (TwistDx, Maidenhead, UK), transcription mediated amplification, emulsion PCR, bridge amplification, isothermal amplification, single strand displacement amplification, rolling circle amplification, whole genome amplification, helicase dependent amplification, nucleic acid sequence-based amplification (NASBA) or any suitable nucleic acid amplification technology. Those of ordinary skill in the art will recognize that certain amplification techniques (e.g., PCR) typically involve RNA reverse transcription to DNA prior to amplification (e.g., RT-PCR), whereas other amplification techniques directly amplify RNA (e.g., TMA and NASBA).
[0083] In some embodiments, a computer-based analysis program is used to translate the raw data generated by the detection assay (e.g., the presence, absence, or amount of a given cancer mutation) into data of predictive value for a researcher or clinician. The researcher or clinician can access the predictive data using any suitable means. Thus, in some embodiments, the present invention provides the further benefit that the researcher or clinician, who may not be trained in genetics or molecular biology, need not understand the raw data. The data is presented directly to the researcher or clinician in its most useful form. The researcher or clinician is then able to immediately utilize the information (e.g., in order to optimize the care of a patient).
[0084] The present invention contemplates any method capable of receiving, processing, and transmitting the information to and from laboratories conducting the assays, information provider, medical personnel, and subjects, patients or participants. For example, in some embodiments of the present invention, a sample (e.g., a biopsy or a serum or urine sample) is obtained from a subject and submitted to a profiling service (e.g., clinical lab at a medical facility, genomic profiling business, etc.), located in any part of the world (e.g., in a country different than the country where the subject resides or where the information is ultimately used) to generate data. Where the sample comprises a tissue or other biological sample, the subject may visit a medical center to have the sample obtained and sent to the profiling center, or subjects may collect the sample themselves (e.g., a saliva, stool, nasal swab, or urine sample) and directly send it to a profiling center. Where the sample comprises previously determined biological information, the information may be directly sent to the profiling service by the subject (e.g., an information card containing the information may be scanned by a computer and the data transmitted to a computer of the profiling center using an electronic communication systems). Once received by the profiling service, the sample is processed and a profile is produced, specific for the diagnostic or prognostic information desired for the subject.
[0085] The profile data is then prepared in a format suitable for interpretation by a user (e.g., treating clinician). For example, rather than providing raw genetic data, the prepared format may represent a diagnosis or risk assessment (e.g., presence or absence of one or more biomarkers and the potential consequences thereof) for the subject, along with recommendations for particular treatment options. The data may be displayed to the clinician by any suitable method. For example, in some embodiments, the profiling service generates a report that can be printed for the clinician (e.g., at the point of care) or displayed to the clinician on a phone, computer monitor, or other device.
[0086] In some embodiments, the information is first analyzed at the point of care or at a regional facility. The raw data is then sent to a central processing facility for further analysis and / or to convert the raw data to information useful for a clinician or patient. The central processing facility provides the advantage of privacy (all data is stored in a central facility with uniform security protocols), speed, and uniformity of data analysis. The central processing facility can then control the fate of the data following treatment of the subject. For example, using an electronic communication system, the central facility can provide data to the clinician, the subject, or researchers.
[0087] In some embodiments, the subject is able to directly access the data using the electronic communication system. The subject may choose further intervention or counseling based on the results. In some embodiments, the data is used for research use. For example, the data may be used to further optimize the inclusion or elimination of markers as useful indicators of a particular condition or stage of disease or as a companion diagnostic to determine a treatment course of action.
[0088] Nucleic acid may be isolated by any means, including the use of commercially available kits. Briefly, wherein the nucleic acid of interest is encapsulated by a cellular membrane, the biological sample can be disrupted and lysed by enzymatic, chemical or mechanical means. The nucleic acid solution may then be cleared of proteins and other contaminants, e.g, by digestion with proteinase K. The nucleic acid is then recovered from the solution. This may be carried out by means of a variety of methods including salting out, organic extraction, or binding of the nucleic acid to a solid phase support. The choice of method will be affected by several factors including time, expense, and required quantity of nucleic acid. All clinical sample types comprising neoplastic matter or pre-neoplastic matter are suitable for use in the present method, e.g, cell lines, histological slides, biopsies, endoscopic brushing sample, paraffin-embedded tissue, body fluids, stool, tissue, colonic effluent, urine, blood plasma, blood serum, whole blood, buffy coat, isolated blood cells, cells isolated from the blood, and combinations thereof.
[0089] Methods of Treatment
[0090] In some embodiments, the present disclosure provides methods for treating a subject (e.g., a patient having or suspected of having cancer or pre-cancer). In accordance with these embodiments, the method includes identifying the presence or absence of one or more biomarkers (e.g., DNA variations, ratios of templates with and without one or more DNA variations) and administering a treatment to the patient based on the results of the biomarker analysis.
[0091] The treatment may be administration of a pharmaceutical compound, a vaccine, performing a surgery, imaging the patient, or performing another test or procedure. In some embodiments, treating a subject includes a method of clinical screening, a method of prognosis assessment, a method of monitoring the results of therapy, a method to identify patients most likely to respond to a particular therapeutic treatment, a method of imaging a patient or subject, and a method for drug screening and development.
[0092] In some embodiments, a method for diagnosing a specific type of disease (e.g., cancer) in a subject is provided. A clinician often makes a diagnosis on the basis of one or more diagnostic indicators, such as for example one or more biomarkers (e.g., DNA sequence variations).
[0093] In some embodiments, clinical cancer prognosis relates to determining the aggressiveness of the cancer and the likelihood of tumor recurrence to plan the most effective therapy. If a more accurate prognosis can be made or even a potential risk for developing the cancer can be assessed, appropriate therapy, and in some instances less severe therapy for the patient can be chosen. Assessment of cancer biomarkers is useful to separate subjects with good prognosis and / or low risk of developing cancer who will need no therapy or limited therapy from those more likely to develop cancer or suffer a recurrence of cancer who might benefit from more intensive treatments.
[0094] As such, in some embodiments, the methods herein comprise determining a risk of developing cancer or determining a prognosis, which can provide for predicting a clinical outcome (with or without medical treatment), selecting an appropriate treatment (or whether treatment would be effective), or monitoring a current treatment and potentially changing the treatment, based on the identification of the diagnostic biomarkers. Further, in some embodiments of the presently disclosed subject matter, multiple determination of the biomarkers over time can be made to facilitate diagnosis and / or prognosis. A temporal change in biomarkers can be used to predict a clinical outcome, monitor the progression of cancer or a subtype of cancer, and / or monitor the efficacy of appropriate therapies directed against the cancer.
[0095] The presently disclosed subject matter further provides, in some embodiments, a method for determining whether to initiate or continue prophylaxis or treatment of a cancer in a subject. In some embodiments, the method comprises providing a series of biological samples over a time period from the subject; analyzing the series of biological samples to identify biomarkers in each of the biological samples; and comparing any measurable change in the biomarkers in each of the biological samples. Any changes over the time period can be used to predict risk of developing cancer, predict clinical outcome, determine whether to initiate or continue the prophylaxis or therapy of the cancer, and whether a current therapy is effectively treating the cancer. For example, a first time point can be selected prior to initiation of a treatment and a second time point can be selected at some time after initiation of the treatment. Biomarkers can be measured in each of the samples taken from different time points and qualitative and / or quantitative differences noted. A change in the biomarker from the different samples can be correlated with a specific cancer risk, prognosis, determining treatment efficacy, and / or progression of the cancer in the subject. In some embodiments, the methods and compositions of the present disclosure are for treatment or diagnosis of disease at an early stage, for example, before symptoms of the disease appear. In some embodiments, the methods and compositions of the present disclosure are for treatment or diagnosis of disease at a clinical stage. In some embodiments, multiple determinations of one or more diagnostic or prognostic biomarkers can be made, and a temporal change in the marker can be used to determine a diagnosis or prognosis. For example, a diagnostic marker can be determined at an initial time, and again at a second time. In such embodiments, a change in the marker from the initial time to the second time can be diagnostic of a particular type or severity of cancer, or a given prognosis. Furthermore, the degree of change of one or more markers can be related to the severity of the cancer and future adverse events. The skilled artisan will understand that, while in certain embodiments comparative measurements can be made of the same biomarker at multiple time points, one can also measure a given biomarker at one time point, and a second biomarker at a second time point, and a comparison of these markers can provide diagnostic information.
[0096] As used herein, the phrase “determining the prognosis” refers to methods by which a clinician can predict the course or outcome of a disease or condition in a subject. The term “prognosis” does not refer to the ability to predict the course or outcome of a condition with 100% accuracy, or even that a given course or outcome is predictably more or less likely to occur based on the identification of biomarkers. Instead, the clinician will understand that the term “prognosis” refers to an increased probability that a certain course or outcome will occur; that is, that a course or outcome is more likely to occur in a subject exhibiting a given condition, when compared to those individuals not exhibiting the condition. For example, in individuals not exhibiting the condition (e.g., lacking one or more mutations), the chance of a given outcome (e.g., suffering from a specific type of cancer) may be very low.
[0097] In some embodiments, a statistical analysis associates a prognostic indicator with a predisposition to an adverse outcome. For example, in some embodiments, a biomarker profile different from that in a normal control sample obtained from a patient who does not have a cancer can signal that a subject is more likely to suffer from a cancer than subjects with a level that is more similar to the biomarker profile in the control sample, as determined by a level of statistical significance. Additionally, a change in biomarker profile from a baseline (e.g., “normal”) level can be reflective of subject prognosis, and the degree of change in biomarker profile can be related to the severity of adverse events. Statistical significance is often determined by comparing two or more populations and determining a confidence interval and / or a p value. See, e.g., Dowdy and Wearden, Statistics for Research, John Wiley & Sons, New York, 1983, incorporated herein by reference in its entirety. Exemplary confidence intervals of the present subject matter are 90%, 95%, 97.5%, 98%, 99%, 99.5%, 99.9% and 99.99%, while exemplary p values are 0.1, 0.05, 0.025, 0.02, 0.01, 0.005, 0.001, and 0.0001.
[0098] In some embodiments, a control sample is analyzed concurrently with the biological sample, such that the results obtained from the biological sample can be compared to the results obtained from the control sample. In some embodiments, one or more positive or negative calibration samples are analyzed simultaneously or sequentially with a biological sample,
[0099] The analysis of markers can be carried out separately or simultaneously with additional markers within one test sample. For example, several markers can be combined into one test for efficient processing of a multiple of samples and for potentially providing greater diagnostic and / or prognostic accuracy. In addition, one skilled in the art would recognize the value of testing multiple samples (for example, at successive time points) from the same subject. Embodiments of the present disclosure also include a kit for performing the methods described herein. The kits comprise embodiments of the compositions, devices, apparatuses, etc. described herein, and instructions for use of the kit. Such instructions describe appropriate methods for preparing an analyte from a sample, e.g., for collecting a sample and preparing a nucleic acid from the sample. Individual components of the kit are packaged in appropriate containers and packaging (e.g., vials, boxes, blister packs, ampules, jars, bottles, tubes, and the like) and the components are packaged together in an appropriate container (e.g., a box or boxes) for convenient storage, shipping, and / or use by the user of the kit. It is understood that liquid components (e.g., a buffer) may be provided in a lyophilized form to be reconstituted by the user. Kits may include a calibrant, positive control, negative control or reference for assessing, validating, and / or assuring the performance of the kit. For example, a kit for assaying the amount of a nucleic acid present in a sample may include a control comprising a known concentration of the same or another nucleic acid for comparison and, in some embodiments, a detection reagent (e.g., a primer, a probe, etc.) specific for the control nucleic acid. The kits are appropriate for use in a clinical setting and, in some embodiments, for use in a user's home. The components of a kit, in some embodiments, provide the functionalities of a system for preparing a nucleic acid solution from a sample. In some embodiments, certain components of the system are provided by the user.
[0100] In some embodiments, the technology described herein is associated with a programmable machine designed to perform a sequence of arithmetic or logical operations as provided by the methods described herein. For example, some embodiments of the technology are associated with (e.g., implemented in) computer software and / or computer hardware. In one aspect, the technology relates to a computer comprising a form of memory, an element for performing arithmetic and logical operations, and a processing element (e.g., a microprocessor) for executing a series of instructions (e.g., a method as provided herein) to read, manipulate, and store data. In some embodiments, a microprocessor is part of a system for determining the presence or absence of a biomarker in a sample (e.g., determining a sequence of a nucleic acid molecule that identifies a chromosomal rearrangement) and for confirming that the biomarker is genuine and not the result of errors introduced by a biological assay (e.g., nucleic acid amplification) performed on the sample.
[0101] In some embodiments, the various embodiments of the present disclosure are associated with a plurality of programmable devices that operate in concert to perform a method as described herein. For example, in some embodiments, a plurality of computers (e.g., connected by a network) may work in parallel to collect and process data, e.g., in an implementation of cluster computing or grid computing or some other distributed computer architecture that relies on complete computers (with onboard CPUs, storage, power supplies, network interfaces, etc.) connected to a network (private, public, or the internet) by a conventional network interface, such as Ethernet, fiber optic, or by a wireless network technology.
[0102] For example, some embodiments provide a computer that includes a computer- readable medium. The embodiment includes a random access memory (RAM) coupled to a processor. The processor executes computer-executable program instructions stored in memory. Such processors may include a microprocessor, an ASIC, a state machine, or other processor, and can be any of a number of computer processors, such as processors from Intel Corporation of Santa Clara, California and Motorola Corporation of Schaumburg, Illinois. Such processors include, or may be in communication with, media, for example computer- readable media, which stores instructions that, when executed by the processor, cause the processor to perform the steps described herein.
[0103] Computers are connected in some embodiments to a network. Computers may also include a number of external or internal devices such as a mouse, a CD-ROM, DVD, a keyboard, a display, or other input or output devices. Examples of computers are personal computers, digital assistants, personal digital assistants, cellular phones, mobile phones, smart phones, pagers, digital tablets, laptop computers, internet appliances, and other processor-based devices. In general, the computers related to aspects of the technology provided herein may be any type of processor-based platform that operates on any operating system, such as Microsoft Windows, Linux, UNIX, Mac OS X, etc., capable of supporting one or more programs comprising the technology provided herein. Some embodiments comprise a personal computer executing other application programs (e.g., applications). The applications can be contained in memory and can include, for example, a word processing application, a spreadsheet application, an email application, an instant messenger application, a presentation application, an Internet browser application, a calendar / organizer application, and any other application capable of being executed by a client device. All such components, computers, and systems described herein as associated with the technology may be logical or virtual.
[0104] In some embodiments, the compositions, systems, kits and methods of the present invention find use in applications wherein accurate and precise measurement of nucleic acid allele frequencies in a sample are desired. In some embodiments, the allele frequency of a target polymorphism is 1% or less. In some embodiments, the allele frequency of a target polymorphism is 1% or greater. In some embodiments, the target nucleic acid is < 170bp. In some embodiments, the target nucleic acid is > 170bp. In some embodiments, the nucleic acid is DNA, for example, genomic DNA, complementary DNA, cell-free DNA (cfDNA), cell-free tumor DNA (cf-tDNA) circulating DNA, exosomal DNA, human DNA, eukaryote DNA, prokaryote DNA and pathogen DNA. In some embodiments, the nucleic acid is RNA, for example, mRNA, rRNA, tRNA, miRNA, siRNA piRNA, human RNA, eukaryote RNA, prokaryote RNA and pathogen RNA. In some embodiments, the sample is a fluid sample, a blood cell sample, a plasma sample, a serum sample, a urine sample, a saliva sample, a CSF sample, a healthy tissue sample, a tumor tissue sample, a biopsy sample and a biopsy margin sample.
[0105] In some embodiments, the 2-step PCR-LAMP amplification methods of the present invention capture, amplify and concatemerize single and multiple cell-free fragmented targets, for example, <170bp in length with clinical accuracy and precision. In some embodiments, the present inventions supports acquisition of same-day diagnostic cell-free DNA data comparable to conventional methods with substantial advantages in cost, time and error reduction. In some embodiments, the present invention provides multiplexed concatemerization of short targets using a 2-step with 1) amplification (e.g., multiplex PCR) to capture and amplify small cf-tDNA fragments, and 2) parallel singleplex LAMP reactor vessels to concatemerize amplification products. EXPERIMENTAL EXAMPLES
[0106] EXAMPLE 1 - Error rate reduction in 9-wide multiplex panel
[0107] Thirty ng of the Wildtype Twist Bioscience (San Francisco, CA) pan-cancer reference panel (Twist #104549) (Figure 3, Figure 4) were used as input to PCR performed with NEB Q5 hotstart 2x master mix. PCR was performed for 35 cycles using the following protocol: 30s @98°C, 35 cycles of 10s @98°C, 30s @ 63°C, 10s @72°C, and a 2min final extension @72°C). One pl of PCR product was added as input to each of 9 LAMP reactor vessels. LAMP was performed using the following reagent mix:
[0108] TABLE 3.
[0109] Each reactor vessel was cycled between 64°C and 68°C for 90 minutes spending Is at each temperature with ramp rates between temperatures set to 1 °C per second. The LAMP products were diluted 6x using nuclease free water combined in equal proportions. lOul of diluted / pooled product were used as input to Oxford Nanopore sequencing kit SQK- RBK1 14.24 according to manufacturer instructions. Sequencing was performed on an Oxford Nanopore RIO.4.1 flow cell and MinlON sequencing device in high accuracy (260bp / s) mode until sufficient coverage was gained to properly evaluate error rates of the device. Nanopore raw output was base-called using Guppy version 6.4.2 “sup” model and aligned to the human reference genome hgl9 using minimap2. The error-corrected results were computed using LAMPrey (Wadden et al., 2022, ibid.) with a confidence level 3. LAMPrey processes concatemeric amplicons and identifies sub-reads for consensus error correction of concatemers. LAMPrey identifies target sequences and expected primer sequences from correct LAMP amplification within the concatemer. LAMPrey then divides each concatemer into sub-reads and aligns them separately to the target sequence. Once each sub-read is aligned, consensus error correction may be applied when or more sub-reads cover the target sequence.
[0110] The error rate was computed by determination of allele frequencies for each evaluated locus as reported by integrated genome viewer version 2.15.1 (IGV) compared to LAMPrey in 3+ confidence mode. Figure 5 shows error rate reduction for 2 loci: PDGFRA D842 and PIK3CA E545 in the Twist Bioscience pa- cancer reference standard. These results show that false positive error rates were reduced by 1.8 fold to 140.7 fold with elimination of specific reduction in error means (z.e., inf errors) using an embodiment of the methods and compositions of the present invention.
[0111] EXAMPLE 2 - Limit-of-detection Analysis in Duplex
[0112] Thirty ng of each allele fraction in the Twist Biosciences pan-cancer reference standard (Twist #104549; 5%, 2%, 1%, 0.5%, 0.25%, 0.1%, 0% / Wt) were used as input to duplex PCR using primers targeting PDGFRA D842 and BRAF V600 loci. Amplification was performed according to manufacturer instructions using the following thermocycler program: (30s @98°C, 35 cycles of 10s @98°C, 30s @ 63°C, 10s @72°C, and then a 2min final extension @72°C). 1 pl of PCR product was used as input to two parallel LAMP. LAMP was performed using the following reagent mix:
[0113] TABLE 4.
[0114] Each reactor vessel was cycled between 64°C and 68°C for 90 minutes spending Is at each temperature. LAMP products were diluted 6x using nuclease free water mixed in equal proportions. lOul of diluted / pooled product were used as input to Oxford Nanopore sequencing kit SQK-RBK114.24 according to manufacturer instructions. Sequencing was performed on an Oxford Nanopore R9.4.1 flow cell and MinlON sequencing device. Thirty thousand aligned reads per target were achieved. Nanopore raw sequencing output was basecalled using Guppy version 6.4.2 and aligned to the human reference genome hgl9 using minimap2 and visualized using Integrated Genome Viewer v2.15.1. Error corrected results were computed using LAMPrey with a confidence level comprising at least 3 concatemer subsections. The 2-step PCR-LAMP duplex assay of the present invention captures fragmented mutant DNA down to -0.25-0.1% variant allele fraction (VAF) (VAF = mutant alleles / mutant alleles + wild-type alleles). For example, an elevation in VAF may accompany growth and / or progression of a tumor. As well, error correction improves resolution of small cf-tDNA VAFs below 1%. In some embodiments, nucleic acid identification error-corrected results are available with 6 hours of sample acquisition using the compositions, methods, systems and kits of the present invention.
[0115] EXAMPLE 3 - Patient plasma sample analysis
[0116] A post-radiation therapy 1ml plasma sample obtained from a pediatric patient with diffuse-intrinsic pontine glioma (DIPG) and a biopsy confirmed H3.3K27M mutation was assayed for H3.3K27M mutant cf-tDNA. The allele frequency in an identical target by a 2- step PCR-LAMP assay of the present invention was compared with the allele frequencies of a conventional droplet digital PCR (ddPCR) assay (Cantor et al. 2022, ibid.) and by UltraPCR assay (Enumerix Inc.) (Shum et al. Next-Generation Digital Polymerase Chain Reaction: High-Dynamic-Range Single-Molecule DNA Counting via Ultrapartitioning. Analytical Chemistry. 2022: https: / / pubs.acs.org / doi / 10.1021 / acs.analchem.2c03649) The H3.3K27M allele fraction was 0.13% by ddPCR, 0.13% by UltraPCR, and 0.13% by the 2-step PCR- LAMP amplification of the present invention. The allele fraction of the negative control was 0.05%. H3.3 K27M allele fraction measured by the 2-step PCR-LAMP amplification of the present invention followed by Nanopore sequencing closely matches the allele fractions measured by ddPCR assay and UltraPCR with significant advantages in costs and time in assay design and validation.
[0117] EXAMPLE 4 - False positive error rates
[0118] Twenty ng of DNA extracted from normal cortex tissue was amplified in 6 separate PCR reactions targeting the H3F3A K27M locus (NEB Q5 HotStart 2x master mix; 0.5uM primer concentration; 30s @ 98C, 35 cycles of (10s @98C, 45s@58C, 10s@72C), 2min @ 72C). PCR amplicons were sequenced using Oxford Nanopore ligation sequencing kit (LSK- SQK114NBD.24) according to manufacturer instructions and sequenced on a MinlON RIO.4.1 flow cell. Resulting signal files were basecalled using Guppy 6.5.7 and aligned to the human genome (hgl9) using minimap2 (v2.17). Allele fractions were computed relative to the reference allele (mut calls / (mut + ref calls)). (Fig. 9) These data indicate that sequencing error rates are highly variable, and are not amenable to detection of low allele frequency circulating tumor DNA.
[0119] EXAMPLE 5 - Comparative false positive error rates
[0120] Fig. 10 shows LAMP sequencing results compared to conventional amplicon sequencing (SQK-LSKNBD.24). LAMP amplicons were generated from H3F3 A K27M Wt DNA and sequenced using Oxford Nanopore SQK-RBK114.24 kit on a MinlON flow cell. Signal files were basecalled using Guppy version 6.5.7 and aligned to the human genome using minimap2 v2.17. LAMP (IGV) allele fractions (red) are computed using Integrated Genome Viewer 2.17 (mut / (mut+Wt)). LAMPrey allele fractions are computed using two different confidence levels considering various concatemer lengths: 1+ (all concatemers), 3+ (only concatemers with 3+ alignable target segments). These data indicate that concatemeric error correction reduces sequencing error rates to levels comparable with existing conventional methodologies such as ddPCR.
[0121] EXAMPLE 6 - Patient plasma samples measured using the LAMP and droplet digital PCR (dd PCR)
[0122] DNA was extracted from plasma samples (~lml) using Qiagen Circulating Nucleic Acid extraction kit (Qiagen) and eluted into 80uL. DNA extracts were vacuum concentrated and amplified for H3F3 A K27M using PCR (as above). Resulting amplicons were diluted 2.5 million fold for analysis using ddPCR. Alternatively, amplicons were re-amplified using PCR reagents and LAMP primers (see below). 2ul of 1 : 50 diluted PCR product from the first round of amplification was used as input to another round of amplification (2ndStage, Table 5.). This product was then used as input to LAMP amplification (Table 6., Table 6.), that was subsequently sequenced using the Oxford Nanopore SQK-RBK114.24 / SQK-RAD114 kit on a MinlON R10.4.1 flow cell. Resulting reads were basecalled (Guppy 6.5.7) and analyzed using LAMPrey with two different confidence levels (all concatemers / l+ or only concatemers with 3+ alignable target segments). (Fig. 11, Fig. 12, Fig. 13, Fig. 14). “Tumor area” was derived from a tumor’s raw millimeter dimensions squared determination by a pathologist determined by taking the largest 2D cross sectional "area" of a tumor from MRI images. “Relative tumor area” compares changes relative to a first measured timepoint. “RT” is radiotherapy. “ONC201” is also referred to as dordaviprone. Radiographic progression is detected by any measurement that passes 150% of an original measured size. Progression free survival (PFS) is the time between a first original measurement and when a tumor area crosses the 150% mark. Clinical progression is determined by a treating oncologist. These data indicate that the methods, compositions, systems and kits of the present invention produce similar results to conventional techniques such as ddPCR, and identifies tumor responses to treatment.
[0123] Table 4.
[0124] Stage 1 (Multiplex PCR; 50ul rxn)
[0125] Singleplex Primer Concentration (25ul rxn) 5ul of 5uM (0.5uM final)
[0126] Multiplex Primer Concentration 5ul of Multiplex mix (~0.25uM final concentration for (50ul rxn) each primer)
[0127] Master Mix 12.5ul / 25ul Q5 hot start 2x master mix
[0128] INCORPORATION BY REFERENCE
[0129] All publications, published patent documents, and patent applications cited herein are hereby incorporated by reference to the same extent as though each individual publication, published patent document, or patent application was specifically and individually indicated as being incorporated by reference.
Claims
CLAIMS1 claim:
1. A method of detecting a target in a sample from a subject, comprising: a) amplifying said target to generate an amplification product; b) amplifying said amplification product with loop mediated amplification (LAMP) wherein said LAMP amplification comprises a forward internal LAMP primer (FIP), a backward internal LAMP primer (BIP), a forward loop primer (FLP) and a backward loop primer (BLP) to generate a LAMP concatemer product; and c) detecting said target in said sample in said LAMP concatemer product.2 The method of claim 1, wherein said amplifying is polymerase chain reaction (PCR) amplification wherein said PCR amplification comprises a forward PCR primer and a reverse PCR primer to generate a PCR amplification product.
3. The method of claim 2, wherein said FIP overlaps no more than 5bp of nucleic acid sequence of said forward PCR primer, and said BIP overlaps no more than 5bp of nucleic acid sequence of said reverse PCR primer.
4. The method of claim 2, wherein said PCR amplification is singleplex PCR or multiplex PCR amplification.
5. The method of claim 1, wherein said amplifying is recombinase polymerase amplification (RPA).
6. The method of claim 1, wherein said sample is a plasma sample or a cerebrospinal fluid (CSF) sample.
7. The method of claim 6, wherein said sample comprises cell-free tumor DNA (cf- tDNA).
8. The method of claim 1, wherein said LAMP amplification is isothermal LAMP amplification or temperature-cycled LAMP amplification.
9. The method of claim 1, wherein said target is less than 170bp in length.
10. The method of claim 1, wherein said sample comprises at least lOng of nucleic acid comprising at least 10 target molecules.
11. The method of claim 1, comprising correcting for sequencing errors wherein a number of concatemer copies with said target is divided by a number of concatemer copies without said target.
12. The method of claim 1, wherein said detecting is sequencing by synthesis sequencing, nanopore sequencing, single molecule real time (SMRT) sequencing, next generation sequencing or third generation long read sequencing.
13. The method of claim 1, further comprising administering an anti-cancer therapy to said subject if said target is detected.
14. A kit, comprising one or more amplification primers, a FIP and a BIP wherein said FIP and said BIP overlap no more than 5 bp of nucleic acid sequence of said one or more amplification primers, a FLP and a BLP.
15. The kit of claim 14, wherein said one or more amplification primers comprises a forward PCR primer and a reverse PCR primer.
16. The kit of claim 14, wherein said one or more amplification primers comprises a forward RPA primer and a reverse RPA primer.
17. The kit of claim 14, comprising one or more nucleic acid isolation reagents.
18. The kit of claim 14, comprising one or more PCR amplification reagents.
19. The kit of claim 14, comprising one or more RPA amplification reagents.
20. The kit of claim 14, comprising one or more LAMP amplification reagents.
21. The kit of claim 14, comprising one or more nucleic acid sequencing reagents.
22. A reaction mixture, comprising: an amplification product from cf-tDNA and one or more LAMP reagents configured to detect a target.
23. A method of amplifying a nucleic acid, comprising: a) amplifying said nucleic acid with PCR amplification to generate a PCR amplification product; and b) amplifying said PCR amplification product with loop mediated amplification (LAMP) to generate a LAMP concatemer product.
24. The method of claims 23, wherein said nucleic acid is cf-tDNA.
Citation Information
Patent Citations
Ultra-sensitive detection of circulating tumor DNA through genome-wide integration
US20210043275A1
Assays and methods for detection of nucleic acids
US20220325363A1
